Abstract
Adjuvant systemic therapy in women with early ER+/HER2+ breast cancer includes chemotherapy (ChT), one year of anti-HER2 therapy and at least five years of hormonal therapy (HT). Here, we explore the impact of de-escalation of adjuvant therapy on the outcome in women with early ER+/HER2+ breast cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
